Impact of the Order of Initiation of Fluconazole and Amphotericin B in Sequential or Combination Therapy on Killing of Candida albicans In Vitro and in a Rabbit Model of Endocarditis and Pyelonephritis
Open Access
- 1 February 2001
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 45 (2), 485-494
- https://doi.org/10.1128/aac.45.2.485-494.2001
Abstract
In vitro time-kill studies and a rabbit model of endocarditis and pyelonephritis were used to define the impact that the order of exposure of Candida albicans to fluconazole (FLC) and amphotericin B (AMB), as sequential and combination therapies, had on the susceptibility of C. albicans to AMB and on the outcome. The contribution of FLC-induced resistance to AMB for C. albicans also was assessed. In vitro, AMB monotherapy rapidly killed each of four C. albicans strains; FLC alone was fungistatic. Preincubation of these fungi with FLC for 18 h prior to exposure to AMB decreased their susceptibilities to AMB for 8 to >40 h. Induced resistance to AMB was transient, but the duration of resistance increased with the length of FLC preincubation. Yeast sequentially incubated with FLC followed by AMB plus FLC (FLC→AMB+FLC) showed fungistatic growth kinetics similar to that of fungi that were exposed to FLC alone. This antagonistic effect persisted for at least 24 h. Simultaneous exposure of C. albicans to AMB and FLC [AMB+FLC(simult)] demonstrated activity similar to that with AMB alone for AMB concentrations of ≥1 μg/ml; antagonism was seen using an AMB concentration of 0.5 μg/ml. The in vitro findings accurately predicted outcomes in our rabbit infection model. In vivo, AMB monotherapy and treatment with AMB for 24 h followed by AMB plus FLC (AMB→AMB+FLC) rapidly sterilized kidneys and cardiac vegetations. AMB+FLC(simult) and FLC→AMB treatments were slower in clearing fungi from infected tissues. FLC monotherapy and FLC→AMB+FLC were both fungistatic and were the least active regimens. No adverse interaction was observed between AMB and FLC for the AMB→FLC regimen. However, FLC→AMB treatment was slower than AMB alone in clearing fungi from tissues. Thus, our in vitro and in vivo studies both demonstrate that preexposure of C. albicans to FLC reduces fungal susceptibility to AMB. The length of FLC preexposure and whether AMB is subsequently used alone or in combination with FLC determine the duration of induced resistance to AMB.Keywords
This publication has 28 references indexed in Scilit:
- Management of Invasive Candidal Infections: Results of a Prospective, Randomized, Multicenter Study of Fluconazole Versus Amphotericin B and Review of the LiteratureClinical Infectious Diseases, 1996
- Combination therapy of murine invasive candidiasis with fluconazole and amphotericin BAntimicrobial Agents and Chemotherapy, 1995
- A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without NeutropeniaNew England Journal of Medicine, 1994
- Pharmacokinetics of fluconazole in cerebrospinal fluid and serum of rabbits: validation of an animal model used to measure drug concentrations in cerebrospinal fluidAntimicrobial Agents and Chemotherapy, 1994
- Secular Trends in the Epidemiology of Nosocomial Fungal Infections in the United States, 1980-1990The Journal of Infectious Diseases, 1993
- Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis.BMJ, 1992
- Interactions in vitro between polyenes and imidazoles against yeastsJournal of Antimicrobial Chemotherapy, 1991
- Hospital-acquired candidemia. The attributable mortality and excess length of stayArchives of Internal Medicine, 1988
- Sensitive bioassay for ketoconazole in serum and cerebrospinal fluidAntimicrobial Agents and Chemotherapy, 1981
- A new look at the statistical model identificationIEEE Transactions on Automatic Control, 1974